Coherus Oncology, Inc. (CHRS)
NASDAQ · Manufacturing · Biological products, (no diagnostic substances)
$1.13−$0.0400 (−3.42%) on the dayAs of the close; data may be delayed.
CHRS price, last 12 months
Key stats
- Previous close
- $1.17
- Open
- $1.17
- Day range
- $1.13 – $1.19
- 52-week range
- $1.09 – $2.62
- Volume
- 1.2M
- Avg volume (20 days)
- 1.3M
- Market cap
- $174.6M
Performance
1W−16.3%
1M−22.1%
3M−24.7%
6M−31.9%
YTD−20.4%
1Y−28.5%
vs S&P 500, 1Y−45.3 pts
Technicals and fundamentals
About Coherus Oncology, Inc.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its portfolio includes LOQTORZI which was developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, by binding to the FG loop on the PD-1 receptor. Company believe blocking PD-1 interactions with PD-L1 and PD-L2 can help to promote the immune systems.
- Sector
- Manufacturing
- Industry
- Biological products, (no diagnostic substances)
- Listed on
- NASDAQ
- Market cap
- $174.6M